Genialis™ krasID: Biology-Driven Machine Learning to Personalize KRAS Inhibitor Therapy
Genialis krasID analyzes foundational aspects of KRAS biology using RNA-sequencing [...]
Prevalence of genomic alterations in Xerna tumor microenvironment subtypes in triple negative breast cancer patients
Abstract:This study investigates the prevalence of genomic alterations in [...]
Prevalence of genomic alterations in Xerna tumor microenvironment subtypes in colorectal cancer patients
This study explores the distribution of genomic alterations in [...]
Profiling microsatellite instability using RNA sequencing data
This study introduces a machine learning model that uses [...]
ResponderID™ KRAS: Biology-Driven Machine Learning to Personalize KRAS Inhibitor Therapeutics
Traditional biomarkers often fail to capture the dynamic nature [...]
Evaluation of a KRAS gene expression signature in lung cancer
This study evaluates the efficacy of a KRAS gene [...]
The Xerna™ TME Panel potentially predicts response to a combination of the TLR9 agonist vidutolimod and PD-1 inhibitor pembrolizumab in metastatic melanomas with prior anti-PD-1 treatment
This poster illustrates the potential of the Xerna™ TME [...]
ResponderID™: The Biology-First Machine Learning Platform for Biomarker Discovery
Rarely has a complex gene signature been successfully translated [...]
Xerna tumor microenvironment subtypes as a biomarker in lung cancer patients
This study investigates the potential of the Xerna™ TME [...]
Predicting benefit from maintenance durvalumab after first-line chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA assay
This study evaluates the efficacy of maintenance durvalumab in [...]
